Highlights & Summary
Liquid Biopsy continued to progress in October, featuring new regulatory milestones, MRD and screening launches, ESMO study results, and notable diagnostics deal activity.
Clinical and Regulatory
1 | FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
The FDA granted Breakthrough Device Designation to Natera’s cfDNA-based MCED assay after incorporating data from 12 cancer types, considering sensitivity, specificity, and cancer signal origin (CSO) performance in their review
Breakthrough Device Designation | Natera
Guardant360 CDx received CE marking within EU IVDR as a companion diagnostic to identify patients with ER-positive, HER2-negative locally advanced / metastatic breast cancer who may benefit from camizestrant, following approvals of the assay for the same drug in the US and Japan
CDx Approval | Guardant Health
3 | Burning Rock’s OncoCompass® Target CDx Kit Enters NMPA Priority Approval Procedure
The Burning Rock Dx OncoCompass Target CDx Kit, an NGS-based liquid biopsy kit for comprehensive genomic profiling using ctDNA, entered the National Medical Products Administration (NMPA) Priority Approval Procedure for Medical Devices, paving the way for approval in China
Regulatory Pathway | Burning Rock Dx
Company Announcements & Product Launches
Abbott announced the commercial availability of the next-generation Oncodetect MRD test, a personalized, tumor-informed MRD assay built on whole-genome sequencing and the Broad Institute-derived MAESTRO enrichment technology
Product Launch | Abbott
Freenome launched SimpleScreen Lung, a cfDNA test for adults 50 to 80 with a >20 pack-year history who are not participating in guideline-recommended screening, expanding the offering to optionally include FDA-approved SimpleScreen CRC from a single blood draw
Product Launch | Freenome
3 | Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Signatera has been selected to identify MRD-positive colorectal cancer patients with no radiographic evidence of disease after curative-intent therapy for enrollment in TransCode’s Phase 2a trial of TTX-MC138, an investigational microRNA-10b inhibitor
Collaboration | Natera, TransCode Therapeutics
Clinical Trials & Study Results
Alliance Foundation Trials and Natera launched the AFT-70 NAVIGATE trial, a phase III trial of more than 2,000 patients with stage II-III ER-positive/HER2-negative early breast cancer; the study tests whether patients with no detectable MRD on Signatera Genome after standard treatment can take Genentech’s investigational oral SERD giredestrant alone, adding a CDK4/6 inhibitor only if Signatera turns positive
Trial Launch | Natera, Alliance Foundation Trials
The COSMOS-MEL01 study represents the first prospective, multicenter study of Guardant Reveal in resected melanoma, which demonstrated 81% sensitivity for recurrence and 100% post-treatment specificity, extending methylation-based MRD evidence beyond the colorectal, breast, and lung cancers where Reveal is currently offered
Study Results | Guardant Health
Abbott’s Beta-CORRECT data compared the whole-genome, MAESTRO-based Oncodetect test with the first-generation whole-exome version in colorectal cancer, with the genome version showing a sensitivity gain for recurrence within two years of surgery, supporting larger variant panels and enrichment to improve post-surgical ctDNA detection
Study Results | Abbott
M&A | VC | Private Equity | Legal
1 | Personalis Reports Expiration of HSR Waiting Period for Proposed Merger With Tempus AI
Personalis reported in an SEC filing that the HSR waiting period for the merger with Tempus AI expired on October 2, clearing the antitrust condition; though closing still requires Personalis stockholder approval, the transaction would fold the tumor-informed NeXT Personal MRD assay into Tempus’ data and AI platform
Merger | Personalis, Tempus AI
EQT Private Equity agreed with QIAGEN’s boards on a recommended all-cash offer of 46.50 euros per share, a premium of about 40 percent to the pre-speculation share price
Public Takeover | EQT, QIAGEN
Myriad announced an agreement to sell its Prenatal Health business, which includes the Prequel, Foresight, SneakPeek, and FirstGene tests (including their cfDNA-based prenatal screen), to Labcorp for $210M, with closing expected by early 2027 subject to regulatory clearance
Divestiture | Myriad Genetics, Labcorp
Additional Sources
Clinical and Regulatory
MCED Trial Guidance | American Cancer Society
Company Announcements & Product Launches
1 | Mammogen and MammoLink Partner to Advance Community-Based Breast Cancer Detection
Clinical Research Partnership | Mammogen, MammoLink
Clinical Trials & Study Results
Study Results | Natera
Study Results | Myriad Genetics







.png)





